JPMDL to Reconsider Proton Pump Inhibitor MDL at July 27 Hearing

nexium-b-1The Judicial Panel on Multidistrict Litigation (JPMDL) will hear arguments at a July 27 hearing on a new motion to centralize proton pump inhibitor (PPI) drugs in a multidistrict litigation. The case is In Re:  Proton-Pump Inhibitor Products Liability Litigation [No. II], MDL Docket No. 2789, JPMDL.

The drugs at issues include Prilosec, Nexium Protonix and Dexilant. The hearing order lists 163 cases in 28 federal district courts and a decision will likely come in mid-August.

Kidney injuries

In their May 31 motion, the moving plaintiffs seek centralization before U.S. Judge David R. Herndon of the Southern District of Illinois.

The plaintiffs allege that PPIs cause kidney injuries including acute interstitial nephritis, chronic kidney disease and end-stage renal disease.

The plaintiffs note that in January, the JPMDL denied centralization of PPI cases, but say later significant developments “warrant a second look at consolidation.”

The defendants are AstraZeneca Pharmaceuticals LP, Proctor & Gamble Co., McKesson Corp., Takeda Pharmaceuticals USA Inc., Novartis Pharmaceuticals Corp., Pfizer Inc. and Pfizer subsidiary Wyeth.  The defendants’ responses are due June 27.

The plaintiff attorneys are Christopher A. Seeger and Jeffrey Grand of Seeger Weiss in New York.


Share this Post: